Lynsight

What an unforgettable few days! The 2025 -GGC Annual Meeting marked a major milestone: 30 years of progress, collaboration, and innovation in the fight against hereditary GI cancer syndromes.

Since 1995, CGA-IGC has built a global community of clinicians, researchers, and advocates dedicated to advancing prevention, diagnosis, and treatment. This year, that spirit was stronger than ever, as we gathered in St. Louis to reflect on our shared history and look boldly toward the future of care.

Thank you to everyone who participated, presented, and contributed to this incredible event. Together, we’re shaping the next chapter in hereditary GI cancer research and care.

If you missed the event, visit our site to learn more about Lynch sydrome testing: https://lynsightlabs.com/lynch-syndrome-testing/

🚨 Last call!

Do you want to help raise Lynch syndrome awareness and advance life-saving testing? Here’s your chance to support the transformation of hereditary cancer diagnostics.

Our patented DiagMMR technology is a true breakthrough: a tumor-independent test capable of detecting Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Help us make early detection accessible for everyone.

Invest today in the future of Lynch syndrome testing:
https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/

New Day Diagnostics

Exciting news from Lynsight!

We’re excited to announce that Lynsight has officially opened its public investment round, offering a chance to join a company that is redefining hereditary cancer diagnostics. Our patented DiagMMR technology represents a true breakthrough: a tumor-independent test that can detect Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Join us in making early detection accessible for all. 💙

Invest in the future of Lynch sydrome testing: https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/